Highlight Therapeutics
- Biotech or pharma, therapeutic R&D
BO-112 is an i.l. administered poly I:C-based nanoplexed dsRNA viral mimetic involved in tumor cell death and immune cell activation mediated by TLR3, MDA5, RIG-I, and PKR. Orphan Drug Designation from FDA granted. Innovation Passport awarded (MHRI).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}